Corcept Therapeutics Integrated (CORT) Q3 2026 Earnings Name Transcript
Corcept Therapeutics Integrated (CORT) Q3 2026 Earnings Name November 3, 2026 5:00 PM EST
Firm Contributors
Atabak Mokari – CFO & Treasurer
Justin Gunn – President of Endocrinology
Roberto Vieira – President of Oncology
Joseph Okay. Belanoff – Co-Founder, President, CEO & Director
Charles Robb
William Guyer – Chief Growth Officer
Convention Name Contributors
Edward Nash – Canaccord Genuity Corp., Analysis Division
David Amsellem – Piper Sandler & Co., Analysis Division
Srikripa Devarakonda – Truist Securities, Inc., Analysis Division
Swayampakula Ramakanth – H.C. Wainwright & Co, LLC, Analysis Division
Presentation
Operator
Howdy, and welcome to the Corcept Therapeutics Q3 2026 Earnings Convention Name. [Operator Instructions] Please be suggested that immediately’s convention is being recorded. It’s now my pleasure to introduce CFO, Atabak Mokari.
Atabak Mokari
CFO & Treasurer
Howdy, everybody. Good afternoon, and thanks for becoming a member of us. Immediately, we issued a press launch asserting our monetary outcomes for the third quarter and offering a company replace. A duplicate is out there at corcept.com. Our full monetary outcomes can be out there after we file our Kind 10-Q with the SEC.
Immediately’s name is being recorded. A replay can be out there on the Buyers Previous Occasions tab of our web site. Statements throughout this name aside from statements of historic reality are forward-looking statements based mostly on our plans and expectations which might be topic to dangers and uncertainties, which could trigger precise outcomes to be materially totally different from these such statements expressed or implied. The dangers and uncertainties which will have an effect on our forward-looking statements are described in our annual report on Kind 10-Okay and our quarterly studies on Kind 10-Q, which can be found on the SEC’s web site.
Please confer with these paperwork for extra data. We disclaim any intention or responsibility to replace forward-looking statements. Our income within the third quarter of 2026 was $340.5 million, a 33% improve from the second quarter and
